BrainSee

A product of Darmiyan

Menu

Pending marketing approval

Breakthrough designated May 28, 2021

Patients & caregivers
Physician access portal
Radiologist MRI guide

What is BrainSee?

BrainSee is a medical software designed to help physicians determine the prognosis of patients who have amnestic mild cognitive impairment (aMCI).

BrainSee’s novel AI algorithm processes a patient’s MRI and cognitive scores and provides a score between 0 and 100 (lower is better) that helps doctors determine the patient’s likelihood of progression from mild cognitive impairment to Alzheimer’s dementia.

The novel technology behind BrainSee

BrainSee was designed and developed based on 40 years of cutting edge neuroscience, artificial intelligence (AI), and thousands of real patient data. BrainSee algorithm processes the patient’s brain MRI scan, pulling critical information that is physiologically relevant to the brain tissue degeneration, and combines it with clinical cognitive test scores to provide a prognostic insight to the physician. Such insight helps doctors choose the best course of treatment or interventions. 

Why use BrainSee instead of PET or CSF biomarkers?
Because BrainSee is …

Non-invasive
Convenient
Accurate
Affordable
Available
Scalable

Users: Medical Doctors

BrainSee is essential for any clinician who evaluates patients with mild cognitive impairment. These clinicians generally include geriatricians, neurologists, psychiatrists, family physicians, and primary care physicians.

Learn More

Benefits of BrainSee

  • For low-risk patients, reassurance can be provided without having to go through invasive tests such as lumbar puncture for CSF biomarker measurements, or amyloid PET (radiotracer injection, radiation exposure, high cost, low accessibility, low positive predictive value). BrainSee can be repeated annually if patient & doctor want continued reassurance and monitoring.
  • For high-risk patients, early interventions (medications, lifestyle changes) may postpone the onset of dementia. Life and care planning can be started early. BrainSee can be repeated quarterly if patient & doctor request additional and continued evaluation.
  • For doctors, BrainSee enables a data driven approach to diagnostic/ prognostic decision making; increases workflow efficiency; and  facilitates a quantitative assessment of the patient’s status with patients and family members. 
Human Brain

Inputs & Output

Inputs:

  • Brain MRI (standard 3D T1, no contrast injection, no radiation)
  • Cognitive test scores (MMSE & CDRSB)

    Note: BrainSee inputs are part of current clinical workup of mild cognitive impairment patients. No extra burden.

Output: An PDF report that provides a prognostic score and instructions on how to interpret it.

Selected Testimonials

“BrainSee unlocks value from brain MRI by providing objective measures for doctors’ prognosis of Alzheimer’s. With FDA approval, Darmiyan will facilitate better patient monitoring and precision medicine.”
Dr. Lawrence Tanenbaum, MD CTO, Director of Advanced Imaging, RadNet
Dr. Lawrence Tanenbaum, MD
“I look forward to making BrainSee widely available, an imaginative new method for non-invasively illuminating and detecting Alzheimer's at stages where interventions might be possible.”
Dr. Alexander Sasha Mark, MDMedical Director, MedStar Radiology Network, Rockfille & Chevy Chase
Dr. Alexander Sasha Mark, MD
BrainSee will be helpful for motivating people to stay the course with the personalized Precision Medicine protocols I use to reverse cognitive decline.
Kat Toups, MD, DFAPAFunctional Medicine Psychiatry and Dementia
Kat Toups, MD, DFAPA